Impax to divest 10 products amid acquisition by Amneal

The Federal Trade Commission (FTC) is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Sanofi suffers setback in insulin monopoly dispute

29 January 2026 A judge has allowed antitrust claims against the pharma giant to move forward, finding that it plausibly used bundled rebates and patent abuse to extend its insulin monopoly, though one allegation was dismissed.

Americas

Eli Lilly’s Mounjaro tops list of cyber squatter targets

28 January 2026 The rise of fake online stores selling counterfeit pharmaceuticals is driving a surge in domain name disputes, forcing major brands to defend revenue and reputation.

Americas

The quantum advantage: IP considerations for the next generation of life sciences innovation

27 January 2026 As quantum-enabled innovation accelerates, patentability will hinge on predictability, disclosure, and modality-specific claim drafting in an increasingly unforgiving enablement landscape, explain Ray Miller and Joseph Wolfe of DLA Piper

More features

Winston & Strawn and Taylor Wessing UK seal ‘powerhouse’ merger

Pearce IP grows practice with senior patent hire

Sanofi suffers setback in insulin monopoly dispute

Firm adds seven-lawyer team in second major merger

Eli Lilly’s Mounjaro tops list of cyber squatter targets

The quantum advantage: IP considerations for the next generation of life sciences innovation

Fed Circ overturns PTAB decision in $83.4m DNA case

Simpson Thacher adds ‘exemplary’ litigator with emerging tech expertise

Impax to divest 10 products amid acquisition by Amneal

More on this story

Editor's picks

Editor's picks

More features